September 2023

Anti-GM-CSF Otilimab versus Tofacitinib ou placebo chez des patients atteints de polyarthrite rhumatoïde active et présentant une réponse inadéquate aux DMARD conventionnels ou biologiques : Deux essais randomisés de phase 3 (contRAst 1 et contRAst 2)

Ann Rheum Dis 2023;0:1–11 doi 10.1136/ard-2023-224482

Fleischmann, et al investigated the safety and efficacy of otilimab versus tofacitinib and placebo in RA patients treated with MTX (contRAst 1) or csDMARDs (contRAst 2). They found that while otilimab achieved the primary endpoint of ACR20 versus placebo in Week 12, it did not demonstrate non-inferiority to tofacitinib.

Keywords:

Otilimab anti-GM-CSF versus Sarilumab ou placebo chez des patients atteints de polyarthrite rhumatoïde et avec une réponse inadéquate aux thérapies ciblées : Un essai randomisé de phase III (contRAst 3)

Ann Rheum Dis. 2023;82(12):1527–1537 doi 10.1136/ard-2023-224449

The ContRAst 3 study investigated otilimab, in RA patients with inadequate responses to multiple treatments. Otilimab did not significantly improve ACR20 versus placebo at Weeks 12 or 24. In addition, there we no significant improvements in secondary endpoints, including disease activity, disability, and pain.

Keywords:

Prévention de la progression radiographique chez les patients à haut risque atteints de polyarthrite rhumatoïde traités par filgotinib dans les études de phase III : Revue narrative des analyses post hoc

Rheumatol Ther. 2023;10(6):1399–1415 doi: 10.1007/s40744-023-00590-w

Findings from post hoc analyses extend the knowledge base for radiographic benefits of filgotinib in patients with RA.

Keywords:

Étude de phase 2a randomisée, en double aveugle, contrôlée par placebo, portant sur l'efficacité et l'innocuité du tildrakizumab chez des patients atteints de spondylarthrite ankylosante active

J Clin Rheumatol. 2023;29(5):223–229 doi: 10.1097/RHU.0000000000001973

Phase 2a study assessing the efficacy and safety of tildrakizumab in patients with active AS fails to meet the primary endpoint.

Keywords:

Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study

Lancet Rheumatol 2023;5:e542–52. doi: 10.1016/S2665-9913(23)00120-0

Week 16 primary outcomes of improved PASI 90 response and sPGA score demonstrated Mirikizumab superiority to placebo and non-inferiority to secukinumab. This study presented results from the OASIS-2 trial on the safety and efficacy of mirikizumab compared with secukinumab and placebo in patients with moderate-to-severe plaque psoriasis.

Keywords:

August 2023

Propriétés différentielles des inhibiteurs de Janus Kinase dans le traitement des maladies inflammatoires à médiation immunitaire

Rheumatology (Oxford) 2023;63(2):298–308 doi 10.1093/rheumatology/kead448

JAKis differ in structure, which affects their inhibitory concentration for different JAKs.

This review by Taylor, et al. compares the pharmacological profiles of JAKis, including abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib, and upadacitinib.

Keywords:

Effet de l'Ixekizumab sur les manifestations axiales chez les patients atteints de rhumatisme psoriasique, d'après deux essais cliniques de phase III : SPIRIT-P1 et SPIRIT-P2

Ther Adv Musculoskelet Dis. 2023;15:1759720X231189005 doi: 10.1177/1759720X231189005

Post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 concludes that ixekizumab (IXE) is effective in improving axial symptoms in patients with active PsA presenting with axial manifestations.

Keywords:

Efficacité du tofacitinib sur l'enthésite chez les patients atteints de rhumatisme psoriasique actif : Analyse des données regroupées de deux études de phase 3

Arthritis Res Ther. 2023 22;25(1):153 doi: 10.1186/s13075-023-03108-5

Post-hoc analysis of two tofacitinib phase three studies concludes that tofacitinib treatment resulted in improvements in enthesitis in patients with PsA, regardless of baseline location or severity.

Keywords:

Différences et similitudes entre les recommandations EULAR/ASAS-EULAR et les recommandations nationales pour le traitement des patients atteints de rhumatisme psoriasique et de spondylarthrite axiale en Europe

Lancet Reg Health Eur. 2023;33:100706 doi: 10.1016/j.lanepe.2023.100706

Comparing the alignment of European national recommendations for patients with PsA and axSpA with EULAR and ASAS-EULAR treatment recommendations found that only a minority of national treatment recommendations were completely aligned.

Keywords:

Efficacité et innocuité du brepocitinib, inhibiteur de TYK2/JAK1, dans le traitement du rhumatisme psoriasique actif : Essai contrôlé randomisé de phase IIb

Arthritis Rheumatol. 2023;75(8):1370–1380 doi: 10.1002/art.42519

Phase IIb study of brepocitinib in patients with PsA concludes that treatment with brepocitinib 30 mg and 60 mg QD, was superior to placebo at reducing signs and symptoms of PsA and was well-tolerated over 52 weeks.

Keywords: